Thank you, Ajay. Now let's review in greater detail the financial results for our third quarter. As previously mentioned, our Q3 revenues were up 10% compared with revenues in the third quarter of the prior fiscal year. Fueled by growth in service revenues, aviation and checkpoint product sales, including trace detection systems, security division revenues in the third fiscal quarter increased 10% year over year to $315 million. In addition, the RF business acquired in fiscal Q1 gained momentum and contributed nicely to security division revenues. Q3 revenues included continued shipments from our contracts in Mexico, though as expected, at a lesser rate as Mexico revenues were $69 million in Q3 at fiscal ‘25 compared to $137 million in the same quarter of the prior year. Revenues, not directly related to acquisitions or our Mexico contracts, increased at a solid double-digit clip in the quarter. Driven by growth in our flex business and also the performance of our core optoelectronics and contract manufacturing operations, third-party opto sales increased 10% year over year to $86 million, representing a new Q3 record. And in the third quarter, our healthcare division achieved the second of back-to-back quarters of top-line growth with a 5% year over year increase. The fiscal ‘25 Q3 gross margin of 33.8% was up 20 basis points from the 33.6% reported in Q3 last year. Our gross margin fluctuates from period to period based on revenue mix and volume, impacts of changes in supply chain costs, FX, tariffs, and inflation, among other factors. Moving on to operating expenses. Q3 SG&A expenses were $73.2 million or 16.5% of sales compared to $66.6 million or 16.4% of sales in Q3 of the prior year. We worked diligently across each of our divisions to improve efficiency and to manage our SG&A cost structure. R&D expenses in Q3 were $18.6 million or 4.2% of revenues compared to $17.1 million, also representing 4.2% of revenues in the same prior year quarter. We continue to dedicate considerable resources to R&D, particularly in our security and our healthcare divisions, as we remain focused on innovative product development, which we view as vital to the long-term success of our businesses. Moving to interest and taxes. While net interest and other expenses decreased sequentially in Q3, on a year-over-year basis, they increased to $8.2 million from $7.4 million in Q3 of fiscal ‘24, primarily due to a higher amount of borrowings associated with the investment in working capital and acquisition completed in Q1 and the stock buyback we did earlier this year as well. This was partially offset by the favorable impact of the convertible notes issued during Q1, which were partially used to repay higher cost borrowings. Our reported effective tax rate under GAAP was 14.3% in Q3 of fiscal ‘25, compared to 22.6% in Q3 last year. Excluding the impact of discrete tax benefits, our normalized effective tax rate, which is the rate reflected in the calculation of non-GAAP adjusted EPS, was 23.7% in Q3 of fiscal ‘25, compared to 23.0% in Q3 of 24. I'll now turn to a discussion of our non-GAAP adjusted operating margin. Overall, our adjusted operating margin in the third quarter of fiscal ‘25 was a solid 14.2%, up from 13.9% in Q3 last year. The Q3 fiscal ‘25 non-GAAP adjusted operating margin in the security division was 18.1%, down year over year from 18.6%, due to a less favorable product mix and increased R&D investment. The opto division's adjusted operating margin increased to 14.0% in the third quarter of fiscal ‘25, from 12.2% in last year's Q3, on economies of scale associated with higher revenues and efficiencies. The healthcare division's adjusted operating margin, while lighter than we would like, was pretty comparable year over year. Moving to cash flow. Q3 marked the second consecutive quarter of significant cash flow, with record cash provided by operations of $82 million. CapEx in the ‘25 third fiscal quarter was $4.5 million, while depreciation and amortization expense in fiscal Q3 was $10.6 million. Solid collections in fiscal Q3 led to a 10% reduction in DSO from Q2, which followed a 16% reduction in DSO in the previous quarter. This reflected more than $100 million received in the third quarter related to our security contracts in Mexico. Our balance sheet is solid, with net leverage of approximately 1.8 as calculated under our credit agreement. Our credit facility requires $7.5 million in annual principal payments under the term loan, with the remainder of our bank debt maturing in fiscal ‘27. Now, turning to guidance. We are increasing our guidance for fiscal ‘25 revenues and non-GAAP diluted EPS. For fiscal year ‘25, we anticipate revenues in the range of $1.69 billion to $1.715 billion, representing an increase in guidance on year-over-year revenue growth to a range of 9.8% to 11.5%. We are also increasing fiscal ‘25 non-GAAP adjusted earnings per diluted share guidance to a range of $9.15 to $9.45, or 12.5% to 16.2% growth. This fiscal ‘25 non-GAAP diluted EPS guidance excludes any impact of potential impairment, restructuring, and other charges, amortization of acquired intangible assets and their associated tax effects, and discrete tax and other non-recurring items. We currently believe this guidance reflects reasonable estimates. The actual impact on the company's financial results of timing changes on the expected conversion of backlog to revenues and new bookings, among other factors, is difficult to predict and could vary significantly from the anticipated impact currently reflected in our guidance. Actual revenues and non-GAAP EPS could also vary from the guidance indicated above due to other risks and uncertainties discussed in our SEC filings. We continue to remain focused on the growth of our businesses and continuing to provide innovative products and solutions. As Ajay mentioned, we'd like to take this opportunity to again thank the global OSI team for its continued dedication in supporting our customers and our partners. And at this time, we'd like to open the call to questions.